key: cord-0792571-k5c7nirf authors: Zarifian, Ahmadreza; Zamiri Bidary, Mohammad; Arekhi, Soheil; Rafiee, Mahdi; Gholamalizadeh, Hanieh; Amiriani, Amirhosein; Ghaderi, Mohammad Sajjad; Khadem‐Rezaiyan, Majid; Amini, Mahnaz; Ganji, Azita title: Gastrointestinal and hepatic abnormalities in patients with confirmed COVID‐19: A systematic review and meta‐analysis date: 2020-07-27 journal: J Med Virol DOI: 10.1002/jmv.26314 sha: 5aad769d44fb92d52f575f0741f5c87317f01cde doc_id: 792571 cord_uid: k5c7nirf Although not common, gastrointestinal and liver symptoms have reportedly been the initial presentation of coronavirus disease‐2019 (COVID‐19) in a large group of patients. Therefore, knowing the frequency and characteristics of these manifestations of COVID‐19 is important for both clinicians and health policy makers. A systematic review and meta‐analysis of the available data on the gastrointestinal and liver manifestations of patients with COVID‐19 was performed. PubMed and Scopus databases and Google Scholar search engine were searched for published and unpublished preprint articles up to 10 April 2020. Original studies providing information on clinical digestive symptoms or biomarkers of liver function in patients with polymerase chain reaction confirmed diagnosis of COVID‐19 were included. After quality appraisal, data were extracted. Prevalence data from individual studies were pooled using a random‐effects model. Overall, 67 studies were included in this systematic review and meta‐analysis, comprising a pooled population of 13 251 patients with confirmed COVID‐19. The most common gastrointestinal symptoms were anorexia (10.2%, 95% confidence interval [CI] = 6.2%‐16.4%), diarrhea (8.4%, 95% CI = 6.2%‐11.2%), and nausea (5.7%, 95% CI = 3.7%‐8.6%), respectively. Decreased albumin levels (39.8%, 95% CI = 15.3%‐70.8%), increased aspartate aminotransferase (22.8%, 95% CI = 18.1%‐28.4%), and alanine aminotransferase (20.6%, 95% CI = 16.7%‐25.1%) were common hepatic findings. After adjusting for preexisting gastrointestinal (5.9%) and liver diseases (4.2%), the most common gastrointestinal findings were diarrhea (8.7%, 95% CI = 5.4%‐13.9%), anorexia (8.0%, 95% CI = 3.0%‐19.8%), and nausea (5.1%, 95% CI = 2.2%‐14.3%). Gastrointestinal and liver manifestations are not rare in patients with COVID‐19, but their prevalence might be affected by preexisting diseases. Diarrhea and mild liver abnormalities seem to be relatively common in COVID‐19, regardless of comorbidities Wuhan, China. [1] [2] [3] As of 27 June 2020, it has infected near 10 million individuals from over 200 countries around the world with around 500 000 deaths, causing a major pandemic. The WHO considered the outbreak of COVID-19 infection as a health emergency. [4] [5] [6] [7] [8] Respiratory symptoms of COVID-19 including fever, dry cough, and dyspnea are the most common manifestations of this novel infectious disease, similar to severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). 9 Although other manifestations such as gastrointestinal symptoms are less common, the initial presentation of the disease in some patients was gastrointestinal symptoms. 9 ,10 Different studies have reported various prevalence rates for gastrointestinal symptoms such as diarrhea in patients with In the SARS epidemic, 16% to 73% of patients had diarrhea during the period of the disease usually in the first week of sickness. In the initial MERS outbreak in 2012, a quarter of patients presented gastrointestinal symptoms such as diarrhea or abdominal pain. Besides, patients with SARS and MERS have showed different degrees of liver injury. 1 Due to the phylogenetic similarities between COVID-19 and previous SARS-like coronaviruses, it is not unlikely that this novel coronavirus infection present with gastrointestinal symptoms in some patients. 10 A growing body of evidence indicates the possibility of gastrointestinal tract and liver being target organs for COVID-19, which can be potentially linked to the fact that the main receptor-mediated entry for the novel coronavirus, angiotensin-converting enzyme 2 (ACE2), is highly expressed in the gastrointestinal tract and the liver. This potential involvement of the gastrointestinal tract can possibly justify the presence of viral RNA in the stool exams of patients, indicating a possibility for fecal-oral transmission of COVID-19. [12] [13] [14] [15] [16] Recognition of clinical characteristics of COVID-19 is not only important for clinicians but also it can be helpful for health policy makers to make proper decisions. 17 Previous systematic reviews on the gastrointestinal and hepatic manifestations of COVID-19 have indicated that gastrointestinal symptoms are relatively common among the patients, with nausea or vomiting, loss of appetite, and diarrhea being the most common symptoms in this regard. However, these studies mostly included merely symptomatic patients and fail to address the effect of comorbid gastrointestinal and liver conditions on the prevalence of these symptoms. 16, 18 In the present study, a systematic review and meta-analysis of the available data on the gastrointestinal and hepatic manifestations of patients with COVID-19 was performed. We also investigated the effect of comorbid gastrohepatic disorders on the rate of gastrointestinal and liver manifestations of COVID-19. Two independent inspectors (MZB and AA) searched PubMed and Scopus databases and Google Scholar search engine for published and unpublished preprint articles from 1 January 2020 to 10 April 2020. Reference list of all selected articles were searched to look for possible missing articles. This search was manually expanded to recognize additional related articles. No language limitations were imposed. Different combinations of the following search terms were used: "Gastrointestinal" OR "Digestive" AND "Liver" OR "Hepatic", AND "Coronavirus Disease 2019." For each term, all synonyms and subjects with the same heading were also searched. After removing the duplicates, five investigators (MZB, MR, HG, AA, and MSG) independently screened the remaining studies for the inclusion criteria. Original studies providing information on clinical digestive symptoms or biomarkers of liver function in patients with reverse-transcriptase polymerase chain reaction confirmed diagnosis of COVID-19 were included in the review, according to current diagnostic guidelines. [19] [20] [21] Letters, comments, review articles, communications, and original articles that did not provide any reliable confirmation of COVID-19 and studies with insufficient data were excluded. To minimize the risk of bias, studies that were conducted exclusively on a specific population and were not representative of the whole range of manifestations (eg, studies only on children, severe and critical cases, fatal cases, etc) were also excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist (Figure 1 ) was followed. The Strengthening the Reporting of Observational studies in Epidemiology checklist was used for critical appraisal to assess the quality of studies. The checklist comprises 22 items, of which six have subitems. Twenty items can be scored a maximum of 1 point while a maximum of 2 points can be allocated to 14 other items where all the criteria regarding a certain item were reported. For each study, the final summed score out of a maximum of 48 points was converted into percentage with a maximum of 100%, to provide a clear estimation. 22 Five investigators independently appraised the papers (MZB, MR, HG, AA, and MSG) and consensus resolved the possible inconsistences. Five investigators (MZB, MR, HG, AA, and MSG) extracted the data from the included studies and possible disagreements were resolved by consensus. Extracted study characteristics were title, journal, first author, publication date, sample size, study type, and origin (country and city). Demographics of the patients including age and gender were extracted and population type (inpatient, outpatient, or both) was recorded. Main gastrointestinal symptoms including diarrhea, vomiting, nausea, anorexia, abdominal pain, and abdominal distension as well as gastrointestinal comorbidities (chronic preexisting gastrointestinal or liver diseases) were extracted as main outcomes. Other main outcomes were markers of liver function, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, total bilirubin, alkaline phosphatase (ALP), and prothrombin time. Regarding the serum levels of these biomarkers, only data from studies with standard reference values and measurement methods were included. Publication bias was kept as minimum as possible by applying no language restrictions and searching different databases. However, in the existence of heterogeneity between studies, potential publication bias was evaluated using funnel plots, Egger's test, and Begg's test. 23, 24 2.6 | Statistical analysis All data were pooled and the meta-analysis was performed using a random-effects model in Comprehensive Meta-analysis version 3.3.070. Point estimates with 95% confidence interval (95% CI) were used to present the results of meta-analysis. The heterogeneity between studies was reported with relevant indicators including I 2 . 25 P < .05 was considered as statistically significant. We repeated the meta-analysis, adjusting for the preexisting gastrointestinal and liver diseases, to investigate the effect of these comorbidities on the prevalence of COVID-19 findings. A subgroup analysis was performed only looking at the published studies (excluding preprint studies). Moreover, we conducted another subgroup analysis according to the severity of disease, to see whether the severity of COVID-19 affects the estimated prevalence of findings. Characteristics of the included studies, including first author, study design, publication date, origin, sample size, and quality assessment score, as well as population type and patient demographics including sex and age are illustrated in Table 1 . Regarding publication bias, funnel plots for two of the common findings are shown in Figures 2 and 3 . Although funnel plots showed asymmetry for some findings, Eggers's test confirmed publication bias only for vomiting (t = 3.47, P < .001). However, the results of the Begg's test showed no notable evidence of publication bias for any of these findings (Table S1 ). This meta-analysis showed that the three most prevalent gastrointestinal symptoms among patients with confirmed COVID-19 were anorexia (10.2%, 95% CI = 6.2%-16.4%), diarrhea (8.4%, 95% CI = 6.2%-11.2%), and nausea (5.7%, 95% CI = 3.7%-8.6%), respectively (Table 2; Figure 4 ). Figure 5 ). Moreover, 18.0% (95% CI = 3.0%-60.8%) showed elevated prothrombin time. Total bilirubin and ALP levels were slightly elevated in 7.8% (95% CI = 5.0%-12.0%) and 4.6% (95% CI = 2.6%-7.9%), respectively. Chronic gastrointestinal and liver diseases were present in 5.9% (95% CI = 4.1%-8.5%) and 4.2% (95% CI = 3.3%-5.3%) of the patients, respectively. When assessing only the published studies, we saw a change in the estimated prevalence of nearly all findings in patients with COVID-19, although the order of the most common findings remained unchanged (Table 2) . Anorexia (16.2%, 95% CI = 10.3%-24.5%) and decreased albumin (39.8%, 95% CI = 15.3%-70.8%) were the most common digestive and hepatic findings, respectively. The prevalence of preexisting gastrointestinal and hepatic findings remained almost the same after exclusion of preprint articles ( Table 2 ). To assess the effect of comorbid gastrointestinal and hepatic conditions on the prevalence of COVID-19 findings, the meta-analysis was repeated, adjusting for these comorbid conditions. The respective results are reported in Table 3 . Overall, after adjusting for chronic preexisting illnesses, the three most common gastrointestinal findings were diarrhea (8.7%, 95% CI = 5.4%-13.9%), anorexia (8.0%, 95% CI = 3.0%-19.8%), and nausea (5.1%, 95% CI = 2.3%-11.0%). Common laboratory abnormalities in liver function were mild reduction in albumin (49.3%, 95% CI = 34.4%-64.4%) and elevations in ALT (19.4%, 95% CI = 9.9%-34.3%) and AST (15.2%, 95% CI = 9.3%-23.8%). As reported by published studies, after adjusting for preexisting illnesses, the most common gastrointestinal feature of COVID-19 was anorexia with an estimated prevalence of 20.0% (95% CI = 9.5%-37.2%), followed by diarrhea (9.9%, 95% CI = 6.5%-14.9%). Table 3 elaborates the details in this regard. Results of the subgroup analysis according to disease severity are illustrated in Table 4 . As is evident from the table, although anorexia was the most common gastrointestinal finding in both subgroups, its prevalence was two times higher in severe patients compared with nonsevere ones (31.4% vs 14.9%). Besides, the prevalence of diarrhea, vomiting, and abdominal pain were also markedly higher in patients with severe disease, while abdominal distension was more frequent in nonsevere cases ( Table 4 ). The severe subgroup showed significantly higher prevalence of liver function abnormalities and preexisting illnesses, as well (Table 4 ). The emergence of the COVID-19 outbreak has infected millions of people worldwide and caused around 500 000 mortalities. The WHO has characterize the infection as a pandemic and called for research on all clinical aspects of COVID-19. Facing this pandemic requires a critical response and preparedness from all communities, especially health care professionals. [6] [7] [8] 92, 93 A variety of symptoms has been reported in patients with COVID-19, from mild pulmonary involvement to severe bilateral pneumonia that can rapidly progress to acute respiratory distress syndrome and respiratory failure. 94 The vast majority of the symptoms associated with COVID-19 are related to respiratory tract, except for general manifestations such as fever. This is in line with the symptoms previously reported in patients with SARS and MERS, which are caused by viruses from the same phylogenic family. 95 The focus of researchers has been on respiratory symptoms, which are thought to be the main cause of fatality in this disease, and T A B L E 1 Characteristics of the studies included in the systematic review and meta-analysis was seen in about 80% of the severe cases. As expected, the prevalence of digestive and hepatic comorbidities were also higher in severe patients, which is in line with the previous reports indicating the higher risk of severe COVID-19 in patients with comorbidities. 96 The higher prevalence of gastrointestinal and liver symptoms among severe cases has been reported in two previous meta-analysis study. 16, 18 Several studies have suggested a relationship between gastrointestinal and hepatic manifestations of COVID-19 and the disease severity in these patients. 32, 100, 101 The results from the meta-analysis by Mao et al 18 are relatively similar to the findings of our main meta-analysis in this study. They reported diarrhea, nausea, or vomiting, and abdominal pain to be present in about 9%, 6%, and 3% of patients, respectively, which is in line with our findings. They also found the prevalence of digestive and hepatic comorbidities to be 4% and 3%, respectively, which is However, similar to these findings, most studies have reported slight elevation of AST, ALT, and bilirubin levels as common findings in COVID-19. 103 The inconsistency in the prevalence of hepatic findings between this review and the previous ones can be attributed to different inclusion and exclusion criteria, as stated before regarding the gastrointestinal findings. The studies that reported high frequency of abnormal liver function are mainly conducted only on severe or fatal cases of COVID-19. 104 As reported in a recent metaanalysis, liver injury is associated with high severity of disease in patients with COVID-19, 105 Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? A novel coronavirus from patients with pneumonia in China Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review Covid-19 and the digestive system World Health Organization Coronavirus disease (COVID-19) Situation Dashboard Rolling updates on coronavirus disease (COVID-19) COVID-19) Situation Report -159 World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission Novel coronavirus infection and gastrointestinal tract Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus Covid-19 and the digestive system Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis [published online ahead of print Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm metaanalysis Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Chinese Center for Disease Control and Prevention Technical Guidance for Prevention and Control of COVID-19 Audio and Video Training Courseware www Centers for Disease Control and Prevention. Interim Guidance on Management of Coronavirus Disease Brain structure and executive functions in children with cerebral palsy: a systematic review Bias in meta-analysis detected by a simple, graphical test Publication bias in meta-analysis: Prevention, assessment and adjustments Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice Clinical and laboratory factors predicting the prognosis of patients with COVID-19: an analysis of 127 patients in Wuhan, China COVID-19 in a designated infectious diseases hospital outside Hubei Province, China Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China Clinical and immunological features of severe and moderate coronavirus disease 2019 Clinical progression of patients with COVID-19 in Shanghai Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Caution: clinical characteristics of COVID-19 patients are changing at admission Clinical features of COVID-19-related liver functional abnormality Early prediction of disease progression in 2019 novel coronavirus pneumonia patients outside Wuhan with CT and clinical characteristics Analysis on the clinical characteristics of 36 cases of novel coronavirus pneumonia in Kunming Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study A tool for early prediction of severe coronavirus disease 2019 (COVID-19): a multicenter study using the risk Nomogram in Wuhan and Guangdong Clinical characteristics of coronavirus disease 2019 in China Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical features of 197 patients infected with 2019 novel coronavirus in Chongqing.China: A single center descriptive study Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to Furin cleavage site Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea Epidemiological and clinical characteristics of 944 cases of 2019 novel Coronavirus infection of non-COVID-19 exporting city A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China Epidemiological and clinical characteristics of 17 hospitalized patients with 2019 novel coronavirus infections outside Wuhan Risk factors related to hepatic injury in patients with corona virus disease Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Analysis of 2019 novel coronavirus infection and clinical characteristics of outpatients: an epidemiological study from the fever clinic in Wuhan Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19) A comparative multi-centre study on the clinical and imaging features of comfirmed and uncomfirmed patients with COVID-19 Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Emerging 2019 novel coronavirus (2019-nCoV) pneumonia Epidemiological characteristics of 2019 novel coronavirus family clustering in Zhejiang Province. Zhonghua yu fang yi xue za zhi Epidemiological and clinical predictors of COVID-19 Comparison of hospitalized patients with acute respiratory distress syndrome caused by COVID-19 and H1N1 Clinical features and treatment of COVID-19 patients in Northeast Chongqing Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Diarrhea is associated with prolonged symptoms and viral carriage in corona virus disease 2019 Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the largest migrant city of China Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 Epidemiologic features and clinical findings of COVID-19-infected patients in Suzhou Manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2 Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua jie he he hu xi za zhi= Chin J Tuberculosis Respir Dis Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city Gastrointestinal tract symptoms in coronavirus disease 2019: analysis of clinical symptoms in adult patients A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study World Health Organization. Responding to community spread of COVID-19: interim guidance World Health Organization. Critical preparedness, readiness and response actions for COVID-19: interim guidance Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study World Health Organization. WHO issues consensus document on the epidemiology of SARS Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China The occurrence of diarrhea in COVID-19 patients Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? Clinical characteristics of 82 death cases with COVID-19 Liver injury is associated with severe Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis Clinical features of 2019 novel coronavirus pneumonia presented gastrointestinal symptoms but without fever onset Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: A systematic review and metaanalysis We authors would like to thank Dr Sajjad Sahab Negah and the Sciences for their cooperation and support. The authors declare that there are no conflict of interests. Data available on request from the authors